TCM
ALNY icon

TD Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

TD Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.92K Hold
23
– – ﹤0.01% 502
2026
Q1 		$7.61K Hold
23
– – ﹤0.01% 503
2025
Q4 		$9.15K Hold
23
– – ﹤0.01% 456
2025
Q3 		$10.5K Hold
23
– – ﹤0.01% 414
2025
Q2 		$7.5K Buy
+23
New +$6.36K ﹤0.01% 456

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Capital Management's ALNY Position: Q2 2026 in Review

TD Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 23 shares worth $6.92K. The position accounts for ﹤0.01% of the portfolio, ranked #502.

TD Capital Management first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.5K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • TD Capital Management held 23 shares of Alnylam Pharmaceuticals worth $6.92K as of Q2 2026.
  • TD Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of TD Capital Management's portfolio in Q2 2026, its #502 holding.
  • TD Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • TD Capital Management's Alnylam Pharmaceuticals position peaked at $10.5K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on TD Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.